Cancer cell metabolism: one hallmark, many faces.

abstract：:Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：:Based on results of the phase III BILCAP study, adjuvant capecitabine should become standard treatment for patients with biliary tract cancer. Among 430 patients who were treated according to the study protocol, capecitabine was associated with a 25% lower risk of death than observation. ...

journal_title：Cancer discovery

authors：

更新日期：2017-07-01 00:00:00

abstract：:A new study of all 32 cancer types in The Cancer Genome Atlas identifies genomic alterations that increase the activity of the PI3K/AKT/mTOR pathway. The study, which combines mutation data with measures of protein levels and phosphorylation status, suggests that mutations in IDH1, VHL, and STK11 promote activation of...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：UNLABELLED:ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. ...

journal_title：Cancer discovery

authors： Shen J,Peng Y,Wei L,Zhang W,Yang L,Lan L,Kapoor P,Ju Z,Mo Q,Shih IeM,Uray IP,Wu X,Brown PH,Shen X,Mills GB,Peng G

更新日期：2015-07-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little improvement in patient outcomes over the past decades. Recently, subtypes of pancreatic cancer with different prognoses have been elaborated; however, the inability to model these subtypes has precluded mechanistic investigation ...

journal_title：Cancer discovery

authors： Miyabayashi K,Baker LA,Deschênes A,Traub B,Caligiuri G,Plenker D,Alagesan B,Belleau P,Li S,Kendall J,Jang GH,Kawaguchi RK,Somerville TDD,Tiriac H,Hwang CI,Burkhart RA,Roberts NJ,Wood LD,Hruban RH,Gillis J,Krasnitz

更新日期：2020-10-01 00:00:00

abstract：UNLABELLED:CD96 has recently been shown as a negative regulator of mouse natural killer (NK)-cell activity, with Cd96(-/-)mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different...

journal_title：Cancer discovery

authors： Blake SJ,Stannard K,Liu J,Allen S,Yong MC,Mittal D,Aguilera AR,Miles JJ,Lutzky VP,de Andrade LF,Martinet L,Colonna M,Takeda K,Kühnel F,Gurlevik E,Bernhardt G,Teng MW,Smyth MJ

更新日期：2016-04-01 00:00:00

abstract：UNLABELLED:Pancreatic ductal adenocarcinoma is refractory to available therapies. We have previously shown that these tumors have elevated autophagy and that inhibition of autophagy leads to decreased tumor growth. Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of Trp5...

journal_title：Cancer discovery

authors： Yang A,Rajeshkumar NV,Wang X,Yabuuchi S,Alexander BM,Chu GC,Von Hoff DD,Maitra A,Kimmelman AC

更新日期：2014-08-01 00:00:00

abstract：:As significant increases in the costs of cancer drugs cause financial difficulties for many U.S. patients, some oncologists suggest that changes in pricing policies at the federal and state levels are inevitable. ...

journal_title：Cancer discovery

authors： Bender E

更新日期：2013-08-01 00:00:00

abstract：:Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment. ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00

abstract：:A recent study integrating proteomic and genomic analyses uncovered unexpected similarities in some types of pediatric brain tumors, such as certain craniopharyngiomas and low-grade gliomas, suggesting potential treatments and more refined prognoses. ...

journal_title：Cancer discovery

authors：

更新日期：2021-01-07 00:00:00

abstract：:According to survival results from a phase II trial of brentuximab vedotin, 34 patients with relapsed or refractory classic Hodgkin lymphoma had a complete response with this CD30-targeting antibody-drug conjugate; 13 remain in remission 5 years later. ...

journal_title：Cancer discovery

authors：

更新日期：2016-09-01 00:00:00

abstract：:The Genomics of Drug Sensitivity in Cancer project recently added 4 years of additional data to a large-scale database designed to identify predictive biomarkers for cancer therapies. Freely available online, these data are driving research on the relationship between genomic features and drug responses to better tail...

journal_title：Cancer discovery

authors：

更新日期：2019-11-01 00:00:00

abstract：:Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues. ...

journal_title：Cancer discovery

authors：

更新日期：2017-10-01 00:00:00

abstract：:A new study by Juergens and colleagues provides the first successful example of a combined epigenetic therapy capable of achieving results similar to those of conventional chemotherapy in refractory metastatic non-small cell lung cancer. Furthermore, the authors describe interesting blood-based DNA methylation biomark...

journal_title：Cancer discovery

authors： Rodríguez-Paredes M,Esteller M

更新日期：2011-12-01 00:00:00

abstract：:Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tu...

journal_title：Cancer discovery

authors： Das RK,Vernau L,Grupp SA,Barrett DM

更新日期：2019-04-01 00:00:00

abstract：:The California Institute of Quantitative Biosciences offers incubators and other programs that aim to close the gap between discovery and commercialization in biotechnology. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：:Researchers have used mass spectrometry to conduct proteomic analyses of 77 genomically characterized breast tumors. Through this approach, they've uncovered functional consequences of somatic mutations. For instance, EGFR overexpression in basal-like breast cancer is potentially driven by the loss of two genes, SKP1 ...

journal_title：Cancer discovery

authors：

更新日期：2016-08-01 00:00:00

abstract：:Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

journal_title：Cancer discovery

authors： Nelson WG,Yegnasubramanian S

更新日期：2013-09-01 00:00:00

abstract：:In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

journal_title：Cancer discovery

authors： Bhat KP,Aldape K

更新日期：2013-07-01 00:00:00

abstract：:Adding stereotactic ablative radiotherapy (SABR) to standard treatment slowed 6-month disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay androgen deprivation therapy, according to findings from the phase II ORIOLE trial. Larger studies are needed to determine if SABR, ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00

abstract：:The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:Kidney cancer is not a single disease but represents several distinct types of cancer that have defining histologies and genetic alterations and that follow different clinical courses and have different responses to therapy. Mutation of genes associated with kidney cancer, such as VHL, FLCN, TFE3, FH, or SDHB, dysregu...

journal_title：Cancer discovery

authors： Linehan WM,Schmidt LS,Crooks DR,Wei D,Srinivasan R,Lang M,Ricketts CJ

更新日期：2019-08-01 00:00:00

abstract：:A recent study suggests that natural killer (NK) cells may play an important role in antitumor response to immune checkpoint inhibitors. Researchers used mouse models to show that NK cells respond to PD-1 and PD-L1 inhibitors, information that could be used to develop immunotherapies that tap NK cells to combat cancer...

journal_title：Cancer discovery

authors：

更新日期：2018-12-01 00:00:00

abstract：:Electronic cigarettes (e-cigarettes) may be an effective tool for smoking cessation. In a randomized trial, researchers found that 18% of those assigned to use e-cigarettes were smoke-free after a year, compared with 9.9% of those assigned to nicotine replacement therapies such as patches and gum. However, those in th...

journal_title：Cancer discovery

authors：

更新日期：2019-04-01 00:00:00

abstract：:Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC-a dissection of mechanisms underlyin...

journal_title：Cancer discovery

authors： Velcheti V,Wong KK,Saunthararajah Y

更新日期：2019-04-01 00:00:00

abstract：:MET is critical for antitumor neutrophil infiltration to HGF-secreting tumors and inflammatory sites. ...

journal_title：Cancer discovery

authors：

更新日期：2015-07-01 00:00:00

abstract：:In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechan...

journal_title：Cancer discovery

authors： Ichihara E,Lovly CM

更新日期：2015-07-01 00:00:00

abstract：:CD30-directed CAR T cells were safe and produced a 62% overall response rate in Hodgkin lymphoma. ...

journal_title：Cancer discovery

authors：

更新日期：2020-09-01 00:00:00

abstract：UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...

journal_title：Cancer discovery

authors： Tanaka K,Babic I,Nathanson D,Akhavan D,Guo D,Gini B,Dang J,Zhu S,Yang H,De Jesus J,Amzajerdi AN,Zhang Y,Dibble CC,Dan H,Rinkenbaugh A,Yong WH,Vinters HV,Gera JF,Cavenee WK,Cloughesy TF,Manning BD,Baldwin AS,Mi

更新日期：2011-11-01 00:00:00